Cargando…

Cell-bound complement activation products associate with lupus severity in SLE

OBJECTIVES: To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4. METHODS: All subjects (n=495) fulfilled the American College of Rheumatology (ACR) classification criteria for SLE. Abnormal CB-CAPs (erythrocy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arriens, Cristina, Alexander, Roberta Vezza, Narain, Sonali, Saxena, Amit, Collins, Christopher E, Wallace, Daniel J, Massarotti, Elena, Conklin, John, Kalunian, Kenneth C, Putterman, Chaim, Ramsey-Goldman, Rosalind, Buyon, Jill P, Askanase, Anca, Furie, Richard A, James, Judith A, Bello, Ghalib A, Manzi, Susan, Ahearn, Joseph, O'Malley, Tyler, Weinstein, Arthur, Dervieux, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228655/ https://www.ncbi.nlm.nih.gov/pubmed/32371480 http://dx.doi.org/10.1136/lupus-2019-000377

Ejemplares similares

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements
por: Putterman, Chaim, et al.
Publicado: (2014)

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2021)

Cell-bound complement activation products in SLE
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2017)

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
por: Wallace, Daniel J, et al.
Publicado: (2019)

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE
por: Petri, Michelle A, et al.
Publicado: (2019)

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice
por: Stohl, William, et al.
Publicado: (2019)

Improving resource utilisation in SLE drug development through innovative trial design
por: Garces, Sandra, et al.
Publicado: (2023)

Clinical response to belimumab in academic clinical practices
por: Reddy, Arthi, et al.
Publicado: (2014)

The global epidemiology of SLE: narrowing the knowledge gaps
por: Barber, Megan R W, et al.
Publicado: (2023)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
por: Askanase, Anca D, et al.
Publicado: (2020)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2016)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

SLE: reconciling heterogeneity
por: Lockshin, Michael D, et al.
Publicado: (2019)

Single-cell RNA sequencing for the study of lupus nephritis
por: Der, Evan, et al.
Publicado: (2019)

Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network
por: Deonaraine, Kristina K, et al.
Publicado: (2021)

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort
por: Mendel, Arielle, et al.
Publicado: (2019)

Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus
por: Mahler, Michael, et al.
Publicado: (2017)

SARS-CoV-2 vaccines in patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice
por: Chu, Seung Y., et al.
Publicado: (2020)

The Use of COVID-19 Vaccines in Patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

SLE clinical trials: impact of missing data on estimating treatment effects
por: Kim, Mimi, et al.
Publicado: (2019)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program
por: Izmirly, Peter, et al.
Publicado: (2019)

Thoughts on COVID-19 and autoimmune diseases
por: Askanase, Anca D, et al.
Publicado: (2020)

A Review of Complement Activation in SLE
por: Weinstein, Arthur, et al.
Publicado: (2021)

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Prevalence of coronary artery calcification in young patients with SLE of predominantly Hispanic and African–American descent
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2019)

Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d
por: Sciascia, Savino, et al.
Publicado: (2022)

Loss of antiphospholipid antibody positivity post-thrombosis in SLE
por: Khawaja, Muznay, et al.
Publicado: (2020)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_otlcafbb54252t9bobf33cdtcs